Skip to Content

Votrient Approval History

  • FDA approved: Yes (First approved October 19th, 2009)
  • Brand name: Votrient
  • Generic name: pazopanib
  • Dosage form: Tablets
  • Company: GlaxoSmithKline
  • Treatment for: Renal Cell Carcinoma, Soft Tissue Sarcoma

Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma.

Development History and FDA Approval Process for Votrient

Apr 26, 2012Approval FDA Approves Votrient for Advanced Soft Tissue Sarcoma
Oct 19, 2009Approval FDA Approves GlaxoSmithKline’s Votrient for Advanced Renal Cell Cancer
Oct  5, 2009GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for Votrient

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.